GSK vs INTC Stock Comparison
GSK currently leads INTC in this stock comparison, with AIQ scores of 66 vs 30. The clearest difference is momentum.
What is the main difference between GSK and INTC?
GSK leads the current stock comparison as GSK plc, with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
GSK plc vs Intel Corp.
GSK leads
GSK leads by 36 AIQ points, primarily on Momentum and Value, and the lead has widened from 18 points over 30 sessions.
Stable: 5 of 6 evidence groups support GSK, its lead is widening, and its current signal state is conflicted.
The Algovestiq AIQ Score currently favors GSK over INTC, 66 versus 30 as of Oct 21, 2026. GSK's advantage is driven primarily by stronger momentum and value. GSK also shows the stronger technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor GSK today, and the comparison is rated Stable on stability: the lead has swung materially session to session. GSK lead: Strengthening — the AIQ differential moved from 18 to 36 points over 30 sessions. GSK leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.
Compare GSK plc and Intel Corp. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare GSK and INTC against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum69 vs 21GSK +48
- Value67 vs 30GSK +37
- Quality73 vs 39GSK +34
- Risk Resilience48 vs 29GSK +19
5 of 6 evidence groups favor GSK. GSK’s edge is concentrated in momentum and value.
What changed since the last close
Latest scored session 2026-10-20, compared against the prior scored session 2026-10-19.
Largest factor move: Momentum +26
New signals
- Keltner Channel Breakout — bullish, volatility, short horizon
No factor moved materially.
No signal started or stopped since the prior session; its 5 active signals are unchanged.
GSK's lead widened by 6 AIQ points in the latest session.
Deeper signal detail for each name lives on its own signals page — GSK and INTC both carry a full feed there.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
GSKGSK on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
GSKGSK on combined revenue and EPS growth.
Value
GSKGSK on the peer-relative Value factor, by 37 points.
Momentum
GSKGSK on the Momentum factor, by 48 points.
Lower downside
GSKGSK on Risk Resilience, by 19 points.
Analyst upside
GSKGSK on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | GSK | INTC | Note |
|---|---|---|---|
| Implied upside to target | +20% | +18.2% | GSK has more room |
| Target dispersion | 0% | +122.9% | Lower is tighter analyst agreement |
| Consensus | Hold | Hold | Context, not a primary driver |
| Analysts covering | 1 | 27 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor GSK. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | GSK | 66 vs 30 |
| Fundamentals | GSKon balance | revenue growth 10.2% vs 18.8%; EPS growth -74.4% vs -195.9%; TTM ROE 28.3% vs -10.8%; gross margin 73.3% vs 38.9% — GSK takes 3 of 4 decided legs, not all of them |
| Valuation | GSK | Value 67 vs 30 |
| Technicals | Even | Price vs 50-day 0.9% vs -9.6%; vs 200-day -3.3% vs 7.8% |
| Risk Resilience | GSK | Risk Resilience 48 vs 29 |
| Analyst expectations | GSK | Target upside 20% vs 18.2% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of GSK and INTC and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 36 points. (supports the conclusion holding)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has swung materially session to session. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on GSK.
How the comparison changed
120 daily snapshots · Jun 21 – Oct 20GSK lead: Strengthening — the AIQ differential moved from 18 to 36 points over 30 sessions.
- Today
- GSK +36
- 66 vs 30
- 7 sessions ago
- GSK +29
- 59 vs 30
- 30 sessions ago
- GSK +18
- 61 vs 43
- 90 sessions ago
- GSK +13
- 55 vs 42
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 1 bearish / 1 neutral, conflicted
Only GSK
- Bollinger Band Squeeze — neutral, volatility, short horizon
- Death Cross Active — bearish, trend, long horizon (5.62%)
- Keltner Channel Breakout — bullish, volatility, short horizon
- MACD Bullish Crossover — bullish, momentum, short horizon
2 bullish / 2 bearish / 1 neutral, conflicted
Only INTC
- Golden Cross Active — bullish, trend, long horizon (20.88%)
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (6.29%)
- Keltner Channel Breakdown — bearish, volatility, short horizon
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
- MACD Bearish Crossover — bearish, momentum, short horizon
GSK leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price is down while the AIQ Score moved up 6 points over the same session — price and model disagree (price -1.2%, AIQ +6 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.39%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1INTC closes the Momentum gap — currently 48 points behind, the largest single contributor to GSK's edge.
- 2INTC's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it.
- 3GSK's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
GSK leads on balance| Metric | GSK | INTC |
|---|---|---|
| Revenue growth (YoY) | 10.2% | 18.8% |
| EPS growth (YoY) | -74.4% | -195.9% |
| Gross margin | 73.3% | 38.9% |
| Operating margin | 24.1% | 0.1% |
| Return on equity (TTM) | 28.3% | -10.8% |
| Debt to equity | 1.03 | 0.58 |
Performance
Split across windows| Metric | GSK | INTC |
|---|---|---|
| 1 week (5 sessions) | 9.4% | -10.8% |
| 1 month (20 sessions) | -0.2% | -26% |
| 3 months (63 sessions) | -0.3% | -10.7% |
| 6 months (126 sessions) | -9.8% | 38.4% |
| Year to date | 3.2% | 148.5% |
| 1 year (252 sessions) | 15.7% | 148.9% |
Technicals
Split| Metric | GSK | INTC |
|---|---|---|
| RSI (14) | 65.1 | 16.4 |
| ADX (14) | 18.7 | 23.3 |
| Price vs 50-day | 0.9% | -9.6% |
| Price vs 200-day | -3.3% | 7.8% |
| Volatility (1M, annualized) | 24.7% | 46.6% |
Risk
GSK is the more resilient| Metric | GSK | INTC |
|---|---|---|
| Beta | 0.23 | 3.08 |
| Sharpe ratio | 0.52 | 1.5 |
| Sortino ratio | 0.9 | 2.73 |
| Max drawdown | -24.4% | -41.9% |
| Current drawdown | -17.2% | -34.9% |
| Annualized volatility | 26.6% | 77.8% |
| Value at risk (95%) | -2.4% | -6.2% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, GSK or INTC?
On the Algovestiq AIQ Score, GSK is the stronger of the two as of Oct 21, 2026, scoring 66 against INTC's 30. The edge comes from momentum and value. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is GSK or INTC the better buy right now?
GSK carries the stronger systematic profile as of Oct 21, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor GSK over INTC?
The composite weights Quality, Value, Momentum and Risk Resilience. GSK leads Momentum by 48 points; GSK leads Value by 37 points; GSK leads Quality by 34 points. GSK leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by INTC simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.
Which has more analyst upside, GSK or INTC?
Analyst price targets imply +20% upside for GSK and +18.2% for INTC, so the Street currently favors GSK. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, GSK or INTC?
GSK is the better-valued of the two on the peer-relative Value factor. GSK on the peer-relative Value factor, by 37 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, GSK or INTC?
GSK on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, GSK or INTC?
GSK on the Momentum factor, by 48 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, GSK or INTC?
GSK is the more resilient of the two, so the other name carries the higher downside risk. GSK on Risk Resilience, by 19 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is GSK more profitable than INTC?
GSK leads on the comparable margin measures — gross margin 73.3% vs 38.9%; operating margin 24.1% vs 0.1%; ttm roe 28.3% vs -10.8%.
Is GSK's lead over INTC getting stronger or weaker?
GSK lead: Strengthening — the AIQ differential moved from 18 to 36 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-06-21 and 2026-10-20. The lead has not changed hands in that window.
What would change the GSK vs INTC verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: INTC closes the Momentum gap — currently 48 points behind, the largest single contributor to GSK's edge; INTC's Keltner Channel Breakdown resolves — a bearish volatility rule currently active against it; GSK's conflicting signal state resolves bearish — it currently carries 2 bullish and 1 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about GSK and INTC?
GSK: 2 bullish / 1 bearish / 1 neutral, conflicted. INTC: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on GSK is Death Cross Active (bearish, long horizon). On INTC it is Golden Cross Active (bullish, long horizon).
Compare GSK and INTC with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.